Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $10.80.

A number of equities analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a research note on Wednesday, October 30th. Oppenheimer reiterated an “outperform” rating and set a $7.00 price objective on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. Finally, StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th.

Regulus Therapeutics Price Performance

RGLS stock opened at $1.49 on Tuesday. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79. The company has a fifty day moving average price of $1.57 and a two-hundred day moving average price of $1.84.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, meeting analysts’ consensus estimates of ($0.17). Research analysts forecast that Regulus Therapeutics will post -0.8 EPS for the current year.

Hedge Funds Weigh In On Regulus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Creative Planning bought a new position in Regulus Therapeutics in the third quarter valued at approximately $26,000. SG Americas Securities LLC acquired a new position in shares of Regulus Therapeutics during the 3rd quarter worth $33,000. Rhumbline Advisers bought a new stake in shares of Regulus Therapeutics during the 2nd quarter worth $136,000. Tyche Wealth Partners LLC boosted its stake in Regulus Therapeutics by 920.6% in the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 95,694 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in Regulus Therapeutics by 56.4% during the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 42,600 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.